Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. 01801
stocks logo

01801

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast 01801 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 01801 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 91.800
sliders
Low
Averages
High
Current: 91.800
sliders
Low
Averages
High
CCBI
CCBI
Outperform
maintain
$125 -> $128
2025-11-07
Reason
CCBI
CCBI
Price Target
$125 -> $128
2025-11-07
maintain
Outperform
Reason
The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year. CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.
CMBI
CMBI
Buy
maintain
2025-10-24
Reason
CMBI
CMBI
Price Target
2025-10-24
maintain
Buy
Reason
The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.
JPMorgan
JPMorgan
maintain
$114 -> $110
2025-10-23
Reason
JPMorgan
JPMorgan
Price Target
$114 -> $110
2025-10-23
maintain
Reason
The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.
CLSA
CLSA
upgrade
2025-10-23
Reason
CLSA
CLSA
Price Target
2025-10-23
upgrade
Reason
The analyst rating for INNOVENT BIO was influenced by the positive outlook stemming from its global strategic collaboration with Takeda Pharmaceutical. CLSA viewed this partnership favorably for INNOVENT BIO's global expansion and product development, particularly in advancing the core project IBI363. As a result of this collaboration, CLSA raised its sales and net profit forecasts significantly for FY26 and made a slight increase for FY27. Consequently, the target price for INNOVENT BIO was increased, and the Outperform rating was maintained.
BofA Securities
BofA Securities
Buy
maintain
$113
2025-10-23
Reason
BofA Securities
BofA Securities
Price Target
$113
2025-10-23
maintain
Buy
Reason
The analyst rating from BofA Securities for INNOVENT BIO was raised to "Buy" due to the company's strategic collaboration with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments. This collaboration is seen as a demonstration of INNOVENT BIO's research and development capabilities and asset value, marking a crucial step towards becoming a multinational pharmaceutical company. As a result, BofA Securities increased its revenue and EPS forecasts for 2026 and 2027, leading to an elevated target price for the stock.
Nomura
Nomura
Buy
maintain
2025-08-28
Reason
Nomura
Nomura
Price Target
2025-08-28
maintain
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for INNOVENT BIO (01801.HK) is 59.33, compared to its 5-year average forward P/E of 74.98. For a more detailed relative valuation and DCF analysis to assess INNOVENT BIO 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
74.98
Current PE
59.33
Overvalued PE
525.06
Undervalued PE
-375.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-43.18
Current EV/EBITDA
70.44
Overvalued EV/EBITDA
122.71
Undervalued EV/EBITDA
-209.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
10.18
Current PS
9.41
Overvalued PS
15.73
Undervalued PS
4.64
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

01801 News & Events

Events Timeline

(ET)
2025-12-01
03:52:00
Innovent Biologics Joins Hang Seng Index as First Biopharma Blue-Chip
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
09:34 AMaastocks
HSI Declines by 102 Points; Technology Stocks Struggle; TECHTRONIC IND Drops Over 2%

  • Market Opening: The Hang Seng Index (HSI) opened 0.4% lower at 25,833, with the HSCEI and HSTECH also experiencing declines of 0.3% and 0.4%, respectively.

  • Constituent Changes: Hang Seng Indexes Company will implement changes to its constituents, including the addition of INNOVENT BIO to the HSI and YUM CHINA to the HSCEI next week.

  • Tech Stock Performance: Major tech stocks like Alibaba and Tencent saw slight declines at market open, while other tech companies like Xiaomi and Meituan also experienced minor fluctuations.

  • Automotive and Export Stocks: Car manufacturers such as Geely and BYD opened lower, while export stocks like Techtronic Industries rose, contrasting with a significant drop in Shenzhou International.

[object Object]
Preview
7.5
09:16 AMaastocks
INNOVENT BIO Finalizes Takeda Introduction, Securing Approximately HKD780M Net

  • Partnership Announcement: INNOVENT BIO has entered a global strategic partnership with Takeda Pharmaceutical, involving a licensing agreement worth USD 11.4 billion and a USD 100 million equity investment from Takeda.

  • Share Issuance Completion: The partnership's conditions have been fulfilled, leading to the issuance of 6.9138 million shares to Takeda, generating nearly HKD 780 million in net proceeds.

[object Object]
Preview
8.5
08:13 AMNewsfilter
Innovent Biologics and Takeda Finalize $11.4 Billion Global Collaboration
  • Collaboration Agreement Finalized: Innovent Biologics and Takeda's global strategic collaboration has become effective, aiming to accelerate the development of next-generation immuno-oncology and antibody-drug conjugate therapies, which is expected to significantly enhance both companies' competitiveness in the global cancer treatment market.
  • Substantial Upfront Investment: Takeda will pay Innovent an upfront payment of $1.2 billion, including a $100 million equity investment, which will provide robust support for Innovent's R&D and market promotion efforts.
  • Milestone Payment Potential: Innovent is eligible for up to $10.2 billion in milestone payments from the development and sales of IBI363, IBI343, and IBI3001, further strengthening its financial position and driving future R&D activities.
  • Global Market Expansion: This collaboration grants Takeda exclusive commercialization rights for IBI363 and IBI343 outside Greater China, marking a significant step in Innovent's international market expansion and enhancing its global influence.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is INNOVENT BIO (01801) stock price today?

The current price of 01801 is 91.8 USD — it has decreased -1.87 % in the last trading day.

arrow icon

What is INNOVENT BIO (01801)'s business?

arrow icon

What is the price predicton of 01801 Stock?

Wall Street analysts forecast 01801 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is INNOVENT BIO (01801)'s revenue for the last quarter?

INNOVENT BIO revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is INNOVENT BIO (01801)'s earnings per share (EPS) for the last quarter?

INNOVENT BIO. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for INNOVENT BIO (01801)'s fundamentals?

The market is revising No Change the revenue expectations for 01801 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.
arrow icon

How many employees does INNOVENT BIO (01801). have?

INNOVENT BIO (01801) has 0 emplpoyees as of December 05 2025.

arrow icon

What is INNOVENT BIO (01801) market cap?

Today 01801 has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free